Cruz et al., 2009 - Google Patents
Enhanced immunogenicity and cross-reactivity of HIV-1 V3-peptide and multiple antigen peptides conjugated to distinct carrier proteinsCruz et al., 2009
View PDF- Document ID
- 8818741692669742636
- Author
- Cruz L
- Cabrales A
- Iglesias E
- Aguilar J
- González L
- Reyes O
- Publication year
- Publication venue
- International immunopharmacology
External Links
Snippet
To be effective, vaccines against the highly variable HIV-1 must elicit antibodies to a huge number of clinical isolates. For this purpose, new strategies to overcome this variability are needed. We previously reported a useful immunogenic strategy which consists of …
- 102000004196 processed proteins & peptides 0 title abstract description 48
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse Transcribing RNA Viruses
- C12N2740/00011—Reverse Transcribing RNA Viruses
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses, e.g. hepatitis E virus
- C07K16/1036—Retroviridae, e.g. leukemia viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
- A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
- A61K47/48238—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying agent being a protein, peptide, polyamino acid
- A61K47/48246—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying agent being a protein, peptide, polyamino acid drug-peptide, protein or polyamino acid conjugates, i.e. the modifying agent being a protein, peptide, polyamino acid which being linked/complexed to a molecule that being the pharmacologically or therapeutically active agent
- A61K47/4833—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying agent being a protein, peptide, polyamino acid drug-peptide, protein or polyamino acid conjugates, i.e. the modifying agent being a protein, peptide, polyamino acid which being linked/complexed to a molecule that being the pharmacologically or therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003529319A (en) | Methods of eliciting broadly neutralizing antibodies targeting HIV-1 gp41 | |
| EP0328403A2 (en) | Synthetic peptides related to the HIV-GP120-env-protein, and their use | |
| US5817318A (en) | Synthetic peptides for an HIV-1 vaccine | |
| Grundner et al. | Factors limiting the immunogenicity of HIV-1 gp120 envelope glycoproteins | |
| NO300462B1 (en) | Monoclonal antibodies and peptides that can be used to diagnose HIV infections | |
| McGaughey et al. | Progress towards the development of a HIV-1 gp41-directed vaccine | |
| Cruz et al. | A comparative study of different presentation strategies for an HIV peptide immunogen | |
| JP2609764B2 (en) | Synthetic peptides for HIV-1 vaccine | |
| US5081226A (en) | Synthetic peptides sharing sequence homology with the HIV envelope protein | |
| US5763160A (en) | Synthetic peptides and process of using same for the detection of antibodies to human immunodeficiency virus (HIV) gp120 envelope protein, diagnosis of AIDS and pre-AIDS conditions and as vaccines | |
| Moseri et al. | An optimally constrained V3 peptide is a better immunogen than its linear homolog or HIV-1 gp120 | |
| Kowalczyk et al. | Strategies and limitations in dendrimeric immunogen synthesis. The influenza virus M2e epitope as a case study | |
| Cruz et al. | Enhanced immunogenicity and cross-reactivity of HIV-1 V3-peptide and multiple antigen peptides conjugated to distinct carrier proteins | |
| Anderson et al. | Hypervariable epitope constructs as a means of accounting for epitope variability | |
| Habte et al. | Immunogenic properties of a trimeric gp41-based immunogen containing an exposed membrane-proximal external region | |
| Du et al. | Effect of trimerization motifs on quaternary structure, antigenicity, and immunogenicity of a noncleavable HIV-1 gp140 envelope glycoprotein | |
| RU2390525C2 (en) | New soluble and stabilised trimeric form of gp41 polypeptides | |
| US20150071954A1 (en) | Stable peptide mimetics of the hiv-1 gp41 pre-hairpin intermediate | |
| Cruz et al. | Different immune response of mice immunized with conjugates containing multiple copies of either consensus or mixotope versions of the V3 loop peptide from human immunodeficiency virus type 1 | |
| EP1704167B1 (en) | A method to make a peptide-carrier conjugate with a high immunogenicity | |
| Iglesias et al. | Broader cross-reactivity after conjugation of V3 based multiple antigen peptides to HBsAg | |
| AU2005223352B2 (en) | Novel Tat complexes, and vaccines comprising them | |
| Cruz et al. | Immunogenicity comparison of a multi‐antigenic peptide bearing V3 sequences of the human immunodeficiency virus type 1 with TAB9 protein in mice | |
| CA2160696C (en) | Peptides for use in vaccination and induction of neutralizing antibodies against human immunodeficiency virus | |
| AU2002231510B2 (en) | Immunogenic formulations of variable peptidic epitopes and process for preparation thereof |